By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Accutane Users Win Huge Verdict Against Roche. Who’s the Winner?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Accutane Users Win Huge Verdict Against Roche. Who’s the Winner?
Policy & Law

Accutane Users Win Huge Verdict Against Roche. Who’s the Winner?

Michael Kirsch
Michael Kirsch
Share
5 Min Read
SHARE

I was engaged in one of my pleasures, sitting in a coffee shop leafing through medical journals. Usually, I am perusing newspapers.

I was engaged in one of my pleasures, sitting in a coffee shop leafing through medical journals. Usually, I am perusing newspapers. I spend many hours each week combing through various newspapers and routinely forward items of interest to folks whom I know would be interested in a particular item or opinion piece. No newspapers today. I have a few gastroenterology journals to look through. My professional reading habits have evolved over my career. I am more interested in reading about medical ethics, health care policy and the art of medicine than in studying hard science or clinical research, which used to be my required reading during my early years.

I read an essay entitled, Irritable Bowel Syndrome (IBS) Patients’ Willingness to Take Risks with Medications published in the June 2012 issue of the American Journal of Gastroenterology. The article stated that IBS patients would accept a small chance of death if there was an overwhelming likelihood of cure. This caught my attention. Of course, IBS can be a debilitating illness. But, it is not cancer and poses no threat to life. Nevertheless, patients who are desperate for succor, would accept a small risk of a premature journey to the hereafter. While many physician would not be comfortable with these odds, if patients make an informed judgment, then it is their call to make.

Patients need to know the material risks of a medicine or treatment in order to provide informed consent. For example, many successful medical malpractice lawsuits prevail because the plaintiff claims that the physician ‘failed to warn’ of a known complication. The plaintiff claims that had he been properly warned of potential rare complication, that he would have rejected the risky and reckless treatment. These cases often suspend disbelief. Do we believe that a patient with a serious medical condition would have declined a treatment if informed about a 1 or 2% chance of a dangerous complication? Give me a break.

More Read

mobile app regulation
Five Tips for Folding FDA’s New Medical App Oversight into Your Business Strategy
HHS Opens New Website-Health Indicators Warehouse For Community Reported Data
Safe Injection Practices: How to Do it Right! [video]
How the Medical Marijuana Industry Is Impacting Big Pharma
10 IT Initiatives Your Hospital Should Undertake in 2012

In New Jersey, a cauldron for medical malpractice litigation, a jury awarded damages of $18 million to two plaintiffs who developed colitis after taking the drug Accutane. They claim that the company, Roche, failed to warn about this complication. There remain over 7000 cases of alleged Accutane induced colitis that are pending. The company Roche has paid out nearly $80 million in verdicts and denies that their medication causes this complication. I wonder how much medical research could have been funded with this incomprehensible amount of cash.

I am a gastroenterologist who has never seen a case of colitis linked to Accutane. I am not certain that this complication truly exists, even though a jury of ordinary folks can accept this, particularly when an ailing person is seeking ‘justice’ from a rich and heartless pharmaceutical company. The first I ever learned of a supposed cnnection between Accutane and colitis was when I read about a medical malpractice case in a newspaper years ago.

Does this drug truly cause colitis? Who knows? Is the company responsible for not warning about a complication that it doesn’t believe exists? Do we believe that a patient with disfiguring acne (Accutane was prescribed for severe acne, not typical teenage blemishes.) would decline a highly effective medicine because there might be an extremely small risk of developing severe colitis? I would suggest that these patients, like suffering IBS patients, would accept considerable risk in return for considerable relief.

In 2009, Roche took Accutane off the market after enduring tens of millions of dollars in verdicts. Who emerges victorious here? Choose the best answer.

  • The public
  • The medical profession
  • Roche
  • Trial Lawyers

Would trial lawyers abandon a case if there was a 1% chance they would lose?

TAGGED:Accutanecolitispharma
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Clinical and Interpersonal Skills That Define Excellence in Patient-Centered Care
Health
June 2, 2026
The Advanced Nursing Credentials That Open Doors to Leadership Roles
The Advanced Nursing Credentials That Open Doors to Leadership Roles
Nursing
June 2, 2026
The Advanced Practice Nursing Roles Worth Knowing About Before You Specialize
The Advanced Practice Nursing Roles Worth Knowing About Before You Specialize
Nursing
June 2, 2026
Language Access in Healthcare: What Hospitals Still Get Wrong in 2026
Hospital Administration Technology
May 29, 2026

You Might also Like

Raise Medicare Age? That’s Cost Shifting, Not Cost Saving

February 28, 2012
Post Acute Care Follow Up Communications
BusinessHospital AdministrationPublic Health

Reducing Avoidable Readmissions: Care Transitions

April 2, 2015

CLL and Lymphoma Drug Approvals: Kudos to the FDA

July 30, 2014

Temporary Health Plans With Low Benefits Continue to Grow

June 8, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?